Gsk (GSK) Receivables - Net (2009 - 2026)

Gsk (GSK) has 18 years of Receivables - Net data on file, last reported at $10.3 billion in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Net rose 5.86% year-over-year to $10.3 billion; the trailing twelve-month figure through Jun 2026 stood at $10.3 billion (up 5.86% YoY), and the FY2025 full-year result was $9.9 billion, up 13.73% from the prior year.
• Receivables - Net was $10.3 billion for Q2 2026 at Gsk, down from $10.5 billion in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $10.8 billion in Q3 2023 to a low of $3.2 billion in Q1 2022.
• A 5-year average of $9.0 billion and a median of $9.0 billion in 2024 frame the typical range for Receivables - Net.
• Across the five-year window, Receivables - Net slumped 63.8% in 2022 and surged 156.3% in 2023, its largest moves.
• Gsk's Receivables - Net stood at $8.3 billion in 2022, then climbed by 10.8% to $9.2 billion in 2023, then retreated by 4.28% to $8.8 billion in 2024, then gained by 13.26% to $9.9 billion in 2025, then rose by 4.04% to $10.3 billion in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $10.3 billion in Q2 2026, $10.5 billion in Q1 2026, and $9.9 billion in Q4 2025.